Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Clinical trial NCT05219318 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05219318
- Sponsor
- University Hospital, Bordeaux
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-23
- Primary completion
- 2027-01-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.